Relationship between long-term use of proton pump inhibitor (PPI) and hypomagnesemia in patients with gastroesophageal reflux disease

Abstract

Background: The aim of this study was to evaluate the relationship between the long-term use of PPI and hypomagnesemia in patients with gastroesophageal reflux disease.

Methods: This case control study was conducted on GERD patients with long-term use of proton pump inhibitor and patients with no history of gastroesophageal reflux and proton pump inhibitor referring to gastrointestinal clinic in 2019. Then concentration of serum magnesium (Mg) and potassium (K) were measured using atomic absorption spectrophotometer according to protocol. Other data were extracted from medical records. Statistical tests such as t-test, chi-square test and ONE WAY ANOVA were used for analysis of data.

Results: In the current study, 263 patients were classified into two groups (case: 132, control: 131). The mean level of potassium in case and control groups was 3.92±0.64 and 4.20±0.43, respectively (P=0.001). Moreover, the mean level of Mg in two groups was 2.03±0.36 and 2.09±0.52, respectively (P=0.24). In addition, significant difference was seen between serum level of K, regarding the type of proton pump inhibitor and duration of medication use (p<0.01). However, no significant difference was seen between serum levels of Mg, regarding the type of proton pump inhibitor such as omeprazole, pantoprazole and other drugs (p>0.05).

Conclusion: Based on these results, long-term use of proton pump inhibitors is not associated with hypomagnesemia in GERD patients. However, long-term use of PPIs may reduce serum potassium levels in these patients. Therefore, periodic evaluation of serum Mg level in PPI-treated patients seems to be unnecessary.

Keywords: Gastroesophageal reflux disease, Hypomagnesemia, Proton pump inhibitor

Citation:
Alvand S, Aghaee B, Momayez Sanat Z. Relationship between long-term use of proton pump inhibitor (PPI) and hypomagnesemia in patients with gastroesophageal reflux disease. Caspian J Intern Med 2022; 13(1): 107-112.

Recently, prevalence of gastroesophageal reflux disease (GERD) has increased in the world including Iran (1, 2). One of the significant effects of GERD is increasing the occurrence of adenocarcinoma of distal esophagus which is directly correlated with GERD (1, 3-7). Risk factors of GERD are environmental factors including obesity, consumption of various foods and genetic factors (1). Proton pump inhibitors (PPIs) are considered as the main basis of treatment for acid-related illnesses, such as GERD, peptic ulcer disease, and functional dyspepsia (8-11). They are one of the most prescribed classes of drugs in primary and specialty care (12). The Food and Drug Administration identified PPIs as effective and safety drugs in 2011 (13, 14), strengthening the importance of long term use of PPIs prescription in this association (8). However, the use of PPI may lead to some adverse events, such as interstitial nephritis (15), clostridium difficile colitis (16), respiratory infections (17), and hip fractures (18).
According to findings, PPIs may induce hypomagnesemia in patients. The association between the use of PPI and symptomatic hypomagnesemia was first described in two patients in 2006 (19). After this report, many reports have supported the association between the use of PPI and induced hypomagnesemia (20-24). The mechanism of PPI-associated hypomagnesemia is related to altered intestinal absorption of magnesium with long-term PPI use (13). In addition, low level of magnesium or hypomagnesemia is associated with variety of adverse events (AEs), such as vomiting, diarrhea, cramps, and even death (25, 26). In addition, hyperkalemia as an adverse effect of PPI therapy was observed in some studies (27, 28); however, another study reported increase in the frequency of hypokalemia after receiving PPIs use (29).

Considering the importance of gastroesophageal reflux disease, the adverse effect of hypomagnesemia was induced by PPI and few and controversial studies regarding long-term use of proton pump inhibitor (PPI) and hypomagnesemia (30, 31). The aim of this study was to evaluate the relationship between the long-term use of proton pump inhibitor (PPI) and hypomagnesemia in patients with gastroesophageal reflux disease. In addition, the relation between the use of PPI and potassium level has been evaluated in these patients.

Methods

This case control study was conducted on GERD patients with long-term use of proton pump inhibitor (at least 1 year) and patients without history of gastroesophageal reflux and proton pump inhibitor referring to gastrointestinal clinic of Shahid Beheshti hospital in Kashan during 2019. The number of patients was assessed according to formula 1 and obtained 132 cases in each group (95 % confidence interval and 80 % power).

\[
n = \frac{(s_1^2 + s_2^2) (z_{1-\alpha/2} + z_{1-\beta})^2}{(x_1 - x_2)^2}
\]

After taking consent from patients, current study was approved by Ethics Committee of Kashan University of Medical Sciences. Inclusion criteria were GERD patients with long-term use of proton pump inhibitor. Exclusion criteria were hypokalemia, symptoms of malabsorption, kidney diseases, endocrine diseases, patient dissatisfaction and the use of diuretics. Data including age, gender, dosage and duration of PPI use were extracted from medical records. Moreover, questions were also asked about the patients’ diets. Two groups were matched in terms of underlying variables.

After collecting blood from patients, serum was separated by centrifuge (Eppendorf) and concentration of magnesium (Mg) and potassium (K) were measured using atomic absorption spectrophotometer (variant 20 plus) according to varian protocol in the laboratory of Shahid Beheshti Hospital. In the next step, the level of magnesium and potassium was compared in two groups.

Statistical analysis: All data were entered to SPSS, Version 16. Statistical tests such as t-test, chi-square test and one way ANOVA were used for data analysis. A p-value < 0.05 was considered statistically significant.

Results

In the current study, 263 GERD patients with long-term use of proton pump inhibitor and patients with no history of gastroesophageal reflux were classified into two groups (case: 132, control: 131). The mean age of patients in case and control was 47.7±11.9 and 55.95±18.8 years, respectively (P=0.001). The duration of medication use was 3.01±2.7 years. Table 1 shows the frequency of variables including gender, proton pump inhibitor type, diuretic intake, and history of disease in case and control groups. Table 2 shows the comparison of case and control groups, regarding serum level of potassium and magnesium.

Table 1: Frequency of variables including gender, proton pump inhibitor type, diuretic intake, and history of disease in case and control groups

| Parameters                        | Case  | Control | Total |
|-----------------------------------|-------|---------|-------|
| **Gender**                        |       |         |       |
| Male                              | 46(34.7) | 65(49.6) | 111(41.8) |
| Female                            | 86(65.2) | 66(50.4) | 152(58.2) |
| **Proton pump inhibitor type**    |       |         |       |
| Omeprazole                        | 92(69.7) | 0 (0) | 92(34.9) |
| Pantoprazole                      | 34(25.8) | 0 (0) | 34(25.8) |
| Other                             | 6 (4.5) | 0 (0) | 6 (2.2) |
| No medication                     | 0 (0) | 131(100) | 131(50) |
| **Diuretic intake**               |       |         |       |
| Yes                               | 0 (0) | 0 (0) | 0 (0) |
| No                                | 132(100) | 131(100) | 263(100) |
| **History of disease**            |       |         |       |
| Mal absorption disease            | 0 | 0 | 0 |
| kidney disease                    | 0 | 0 | 0 |
| Glandular disease                 | 0 | 0 | 0 |
Table 2: Comparison of case and control groups, regarding serum level of potassium and magnesium

| Parameters          | Case       | Control    | p-value |
|---------------------|------------|------------|---------|
| Potassium (mEq/L)   | 3.92±0.64  | 4.20±0.43  | 0.001   |
| Magnesium (mg/dl)   | 2.03±0.36  | 2.09±0.52  | 0.24    |

* Independent T test

As shown in table 2, there was a significant difference between case and control groups, regarding serum level of potassium (p<0.01). But no significant difference was observed between case and control, regarding the level of serum magnesium (p>0.05). Table 3 shows frequency of serum level of magnesium and potassium in case and control group. The relationship of serum magnesium and potassium level with duration of medication use is shown in table 4.

Table 3: Frequency of serum level of magnesium and potassium in case and control groups

| Parameters          | Case       | Control    | p-value |
|---------------------|------------|------------|---------|
| Serum magnesium level |           |            |         |
| Hypomagnesemia (<1.7 mg/dl) | 16 (12.1) | 18 (13.7) |         |
| Normal (1.7-2.6 mg/dl)         | 110(83.3) | 105 (80.1)|         |
| Hypermagnesemia (>2.6 mg/dl)   | 6 (4.5)   | 8 (6.1)   |         |
| Serum potassium level      |           |            |         |
| Hypokalemia(<3.5 mEq/L)     | 29 (22)   | 4 (3.1)   |         |
| Normal (3.5-5 mEq/L)        | 103 (78)  | 122 (93.1)|         |
| Hyperkalemia (>5 mEq/L)     | 0         | 5 (3.8)   |         |

Table 4: The relationship of serum magnesium and potassium level with duration of medication use

| Elements          | Duration of medication use (year) | p-value |
|-------------------|----------------------------------|---------|
| Hypomagnesemia    | 1.43±2.19                        | 0.903   |
| (<1.7 mg/dl)      |                                  |         |
| Normal (1.7-2.6 mg/dl) | 1.51±2.49 |                      |         |
| Hypermagnesemia   | 1.78±2.99                        |         |
| (>2.6 mg/dl)      |                                  |         |
| Hypokalemia(<3.5 mEq/L) | 2.85±1.92 | <0.001              |
| Normal (3.5-5 mEq/L) | 1.35±2.5 |                      |
| Hyperkalemia (>5 mEq/L) |          |                      |

* One way anova

As demonstrated in table 4, there was a significant relationship between serum levels of potassium and duration of medication use (p<0.01). The mean age of patients in hypomagnesemia (<1.7 mg/dl), normal (1.7-2.6 mg/dl) and hypermagnesemia groups (>2.6 mg/dl) was 56.4±14.4, 52.2±16.6 and 45.4±10.2, respectively. In addition the mean age of patients in hypokalemia (<3.5 mEq/L), normal (3.5-5 mEq/L) and hyperkalemia groups (>5 mEq/L) was 49.2±10.3, 53±16.8 and 45.4±18.4, respectively. The relationship between serum level of elements including Mg and K with age groups showed that there was no significant relation between Mg and K level and age groups (P=0.09). Moreover, no relation was seen between age and elements such as potassium level (P=0.29). Frequency comparison of two groups (male and female groups), regarding serum level of magnesium and potassium showed that there was no significant difference between frequency of patients in two groups, regarding magnesium (P=0.218) and potassium (P=0.175).

Serum level of potassium in omeprazole, pantoprazole and other drug groups was 1.99±0.35, 2.07±0.31 and 2.30±0.68, respectively. In addition, the mean level of potassium in 3 groups was 3.94±0.54, 3.84±0.89, and 4.18±0.45, respectively. In addition, One way ANOVA test showed a significant difference between 3 groups, regarding serum level of potassium (P=0.001). However, no significant difference was seen between these groups (omeprazole, pantoprazole and other drugs groups), regarding serum level of magnesium (P=0.226).

Discussion

PPIs are a mainstay treatment for gastric acid related diseases (32). There is clinical concern regarding PPI-induced hypomagnesaemia as a consequence of long-term PPI use. PPI induced hypomagnesaemia leads to symptoms including convulsions, cardiac arrhythmia, tetany, seizures, and convulsion. It also exposes patients at risk for secondary electrolyte disturbances like hypocalcemia (32). However, drug-induced hypomagnesemia is not unique to PPI. Other classes of drugs including diuretics, gentamycin (33) platinum-based cytostatic, calcineurin inhibitors, epidermal growth factor receptor (EGF-R) targeting drugs have been associated with hypomagnesemia (34, 35).

In our study, no significant difference was observed between case and control, regarding the levels of serum magnesium. It indicates that the use of proton pump inhibitor (PPI) did not affect the level of serum magnesium compared to control group.
The role of studies about the use of PPIs in hypomagnesemia is a controversy. Koulouridis et al., reported that the use of PPI was not associated with hypomagnesemia during admission in the hospitals (30). Chowdhry et al., evaluated the role of PPIs on 2400 patients with hypomagnesemia and reported that no significant difference was seen between the mean level of magnesium in PPI users and nonusers. The findings of two studies were consistent with our study. Moreover, according to these findings, taking PPIs in different doses, with or without concomitant diuretics was not associated with hypomagnesemia. Therefore, it seems that routine screening of serum magnesium in PPI may be unnecessary (36).

Dunkin et al., revealed the lower level of serum Mg level in patients receiving PPI therapy than those not receiving PPIs (31). These findings imply that long-term use of PPIs was associated with Mg deficiency and insufficiency status. The mechanism that illustrates the cause of lower serum level of Mg in patients receiving PPIs is not clear (31). They reported that one limitation of this study was that data of serum magnesium level before treatment in these patients were unavailable; which was consistent with our study.

Douwes et al., reported that the use of PPIs in kidney transplant recipients was associated with the risk of hypomagnesemia. They reported that the plasma level of magnesium was lower in PPI users, indicating that hypomagnesemia was caused by impaired gastrointestinal absorption compared to renal magnesium wasting (37). It is assumed that PPIs inhibit the absorption of active magnesium via TRPM 6 and 7 channels in the intestine (37). Cheungpasitporn et al., reported that the use of PPIs was associated with hypomagnesemia and cardiovascular events. Moreover, they believed that physicians should consider the patients who are taking PPIs are at risk for cardiovascular events from hypomagnesemia, particularly those who have impairment in gastrointestinal absorptive capacity for magnesium and renal losses of magnesium due to diuretics or poor nutrition (38). Hess et al., in another study reported hypomagnesemia in 13% of PPIs users. They reported that single nucleotide polymorphism in TRPM6 (rs3750425 and rs2274924) increases the risk for PPI-induced hypomagnesemia approximately 5.8-fold (39). Therefore, according to this finding, single nucleotide polymorphism of some genes can increase the risk for PPI-induced hypomagnesemia. Luck et al., reported that the patient’s age is an influential factor on hypomagnesemia and older patients had a higher risk of developing hypomagnesemia (26). Therefore, the development of hypomagnesemia in patients using PPIs is influenced by several factors. In our study, 70% of females using PPIs had hypomagnesemia, whereas 29% of males had hypomagnesemia. But no significant relation was seen between serum magnesium level with age and sex. Dunkin et al., reported that although female PPIs users had lower serum level of Mg than males, the mean serum magnesium level was independent of gender and age, which was consistent with our study. The cause of lower level of serum Mg in women compared to men was unclear (31). In addition, no significant difference was seen between serum levels of magnesium, regarding the type of proton pump inhibitor such as omeprazole, pantoprazole and other drugs. It appears that the type of PPIs did not affect the serum level of magnesium. Dunkin et al., reported that mean serum level of Mg in esomeprazole users was higher than those using omeprazole or pantoprazole, whereas no significant difference was observed between these groups, which was consistent with our study (31).

In the current study, the mean level of potassium in case group (3.92±0.64) was significantly lower than the control group (4.20±0.43). Maede et al., revealed that the use of omeprazole decreased serum potassium level via accelerating urinary potassium excretion. Our findings were consistent with Maede’s study, regarding the serum level of potassium (40). Wainwright et al., reported that though some potassium is lost from the stomach, renal excretion of potassium is the primary cause of hypokalemia. They also revealed that vomiting can lead to hypokalemia via two pathways. First; gastric acid loss leads to hypochloraemic metabolic alkalosis which increases filtered bicarbonate load in the nephron and subsequently increases distal sodium bicarbonate delivery. Secondly, hypovolemia causes activation of the renin-angiotensin-aldosterone axis. Standard treatment of severe hypokalemia in patients with bulimia nervosa, anorexia and persistent self-induced vomiting includes intravenous replacement of potassium and correction of hypovolemia (41). In addition, the significant difference was seen between serum levels of potassium, regarding the type of proton pump inhibitor and duration of medication use. At the time of PPI administration, it seems necessary to pay attention to the duration of medication use and the type of proton pump inhibitor.

In conclusion, based on these results, long-term use of proton pump inhibitors is not associated with
hypomagnesemia in GERD patients. However, long-term use of PPIs may reduce serum potassium levels in these patients. Therefore, the periodic evaluation of serum Mg level in PPI-treated patients seems to be unnecessary. Furthermore, more studies should be done regarding the level of potassium after the long-term use of proton pump inhibitor.

**Acknowledgments**

We thank the hospital staff of Shahid Beheshti of Kashan

**Funding:** None

**Conflict of Interest:** There is no conflict of interest.

**References**

1. Ehsani M, Maleki I, Mohammadzadeh F, Mashayekh A. Epidemiology of gastroesophageal reflux disease in Tehran, Iran. J Gastroenterol Hepatol 2007; 22: 1419–22.
2. Axon AT. Personal view: to treat or not to treat? Helicobacter pylori and gastro-oesophageal reflux disease– an alternative hypothesis. Aliment Pharmacol Ther 2004; 19: 253–61.
3. Shammas MA, Koley H, Beer DG, et al. Growth arrest, apoptosis, and telomere shortening of Barrett’s associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology 2014; 126: 1337–46.
4. Tutuian R, Castell DO. Gastroesophageal reflux disease: natural history and long-term medical and surgical outcomes. Clin Cornerstone 2003; 5: 51–60.
5. Spechler SJ. Esophageal complications of gastroesophageal reflux disease: presentation, diagnosis, management, and outcomes. Clin Cornerstone 2003; 5: 41–50.
6. Soll AH, Fass R. Gastroesophageal reflux disease: presentation and assessment of a common, challenging disorder. Clin Cornerstone 2003; 5: 2–17.
7. Toruner M, Soykan I, Ensari A, et al. Barrett’s esophagus: prevalence and its relationship with dyspeptic symptoms. J Gastroenterol Hepatol 2004; 19: 535–40.
8. Park Ch, Kim E, Ho Roh Y, Yan Kim H, Kil Lee S. The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia: A Systematic Review and Meta-Analysis. PLoS One 2014; 9: e112558.
9. Lacy BE, Talley NJ, Locke GR, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012; 36: 3–15.
10. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008;135: 1383–91
11. Xiao Y, Peng S, Tao J, et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol 2010; 105: 2626–31.
12. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011; 56: 931–50.
13. Reed LG, Mok JY. Proton pump inhibitor-associated hypomagnesemia: A retrospective case-control study. Fed Pract 2016; 33: 18-21.
14. FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs. FAD 2017. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-low-magnesium-levels-can-be-associated-long-term-use-proton-pump
15. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor- associated acute interstitial nephritis. Aliment Pharmacol Ther 2007; 26: 545–53.
16. Howell MD, Novack V, Grgrich P, Soulliard D, Novack L. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170: 784–90.
17. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009; 301: 2120–8.
18. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 2010; 170: 765–71.
19. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006; 355: 1834–6.
20. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol 2008; 69: 338–41.
21. Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009; 151: 755-6.
22. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors—a review. Neth J Med 67: 169–72.
23. Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010; 56: 112–16.
24. Regolisti G, Cabassi A, Parenti E, Maggiore U, Fiaccadori E. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 2010; 56: 168–74.
25. Danziger J, William JH, Scott DJ, et al. Proton pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013; 83: 692-9.
26. Luk CP, Parsons R, Lee YP, Hughes JD. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 2013; 47: 773-80
27. Gau JT, Heh V, Acharya U, Yang YX, Kao TC. Uses of proton pump inhibitors and serum potassium levels. Pharmacoepidemiol Drug Saf 2009; 18: 865–71.
28. Tashiro M, Yoshikawa I, Kume K, et al. Acute hyperkalemia associated with intravenous omeprazole therapy. Am J Gastroenterol 2003; 98: 1209–10.
29. Makunts T, Cohen IV, Awdish L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019; 9: 2282.
30. Koulouridis I, Alfayez M, Tighiouart H, et al. Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis 2013; 62: 730-7.
31. Dunkin S, Punam S. Association of proton pump inhibitor with hypomagnesaemia: a cross-sectional study at a tertiary care hospital of and district. Indian J Pharm Prac 2014; 7: 10-15.
32. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012; 36: 405–13.
33. Chou CL, Chen YH, Chau T, Lin SH. Acquired bartter-like syndrome associated with gentamicin administration. Am J Med Sci 2005; 329: 144–9.
34. Ledeganck KJ, Boulet GA, Horvath CA, et al. Expression of renal distal tubule transporters TRPM6 and NCC in a rat model of cyclosporine nephrotoxicity and effect of EGF treatment. Am J Physiol Renal Physiol 2011; 301: F486–93.
35. Dimke H, van der Wijst J, Alexander TR, et al. Effects of the EGFR inhibitor erlotinib on magnesium handling. J Am Soc Nephrol 2010; 21: 1309-16.
36. Chowdhry M, Shah K, Kemper S, et al. Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use. Journal of gastroenterology and hepatology 2018; 3: 1717-21.
37. William JH, Danziger J. Proton-pump inhibitor-induced hypomagnesemia: Current research and proposed mechanisms. World J Nephrol 2016; 5: 152–7.
38. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 2015; 37: 37-41.
39. Hess MW, de Baaij JH, Broekman MM, et al. Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitor-induced hypomagnesemia: a case–control study. Pharmacogenet Genomics 2017; 27: 83-8.
40. Maeda Y, Kojima N, Araki Y, et al. Does a proton pump inhibitor cause hypokalemia? Intern Med 2011; 50: 1045-50.
41. Wainwright N, Azim A, Neary J. Proton pump inhibition in the management of hypokalemia in anorexia nervosa with self-Induced vomiting. General Intern Med 2018; 13: 35-8.